Provider preferences for resolving uncertainty and avoiding harms in precision medicine: a discrete choice experiment-Reference-Cited by-同舟云学术

Provider preferences for resolving uncertainty and avoiding harms in precision medicine: a discrete choice experiment

Published:2020-09 Issue:5 Volume:17 Page:389-398
ISSN:1741-0541
Container-title:Personalized Medicine
language:en
Short-container-title:Personalized Medicine

Author:

Hendrix Nathaniel¹^ORCID,Regier Dean A²³^ORCID,Chatterjee Jagori⁴,Dhanda Devender S¹^ORCID,Basu Anirban¹^ORCID,Veenstra David L¹^ORCID,Carlson Josh J¹^ORCID

Affiliation:

1. The Comparative Health Outcomes, Policy, & Economics (CHOICE) Institute, University of Washington, Seattle, WA 98195, USA

2. Canadian Centre for Applied Research in Cancer Control (ARCC), Cancer Control Research, BC Cancer, Vancouver, BC V5Z 1L3, Canada

3. School of Population & Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada

4. Department of Economics, Furman University, Greenville, SC 29613, USA

Abstract

Background: Substantial uncertainty exists about how providers assess the value of genomic testing. Materials & methods: We developed and administered a discrete choice experiment to a national sample of providers. We analyzed responses using an error components mixed logit model. Results: We received responses from 356 providers. The attributes important to providers were patient health and function, life expectancy, cost, expert agreement, and biomarker prevalence. Providers significantly valued reducing uncertainty only when it eliminated the possibility of decreased life expectancy. Providers valued improving certainty about life expectancy gains from 12 ± 18 to 12 ± 6 months at US$400 (US$200–600) versus US$200 (-US$60–500) for 4 ± 4 to 4 ± 2 years. Conclusion: Providers value resolving uncertainty most when it eliminates the possibility of substantial harm.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Molecular Medicine,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pme-2020-0018

Reference30 articles.

1. Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care

2. Characterizing Pharmacogenomic-Guided Medication Use With a Clinical Data Repository

3. Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine

4. Genomic medicine in primary care: barriers and assets: Table 1

5. Understanding the Medical and Nonmedical Value of Diagnostic Testing

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protocol for a type 3 hybrid implementation cluster randomized clinical trial to evaluate the effect of patient and clinician nudges to advance the use of genomic medicine across a diverse health system;Implementation Science;2024-08-19

2. A Systematic Review of Discrete Choice Experiments and Conjoint Analysis on Genetic Testing;The Patient - Patient-Centered Outcomes Research;2021-06-04

3. Toward the diagnosis of rare childhood genetic diseases: what do parents value most?;European Journal of Human Genetics;2021-04-26